|1.||Murrieta-Aguttes, M: 3 articles (07/2001 - 03/2000)|
|2.||Bachert, Claus: 2 articles (11/2011 - 09/2002)|
|3.||Leynadier, Francisque: 2 articles (04/2003 - 09/2002)|
|4.||Leynadier, F: 2 articles (04/2000 - 03/2000)|
|5.||Feng, Shuibin: 1 article (01/2015)|
|6.||Suo, Jinping: 1 article (01/2015)|
|7.||Nie, Lei: 1 article (01/2015)|
|8.||Zou, Peng: 1 article (01/2015)|
|9.||Carter, Ben: 1 article (01/2014)|
|10.||Bennett, Cathy: 1 article (01/2014)|
03/01/1999 - "Overall, mizolastine 10 mg/day was found to be significantly more effective than placebo and as effective as other second generation antihistamine drugs in the management of patients with chronic urticaria, with a rapid and sustained action."
05/01/1996 - "Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria."
05/01/1996 - "Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria."
03/01/2000 - "To assess the long-term safety and efficacy of the H1-receptor antagonist mizolastine in the symptomatic treatment of chronic urticaria (CU). "
01/01/2000 - "A second-generation antihistamine, mizolastine, which exhibits dual activity with selective H1-receptor antagonism and, as shown in animal studies, anti-5-lipoxygenase activity, represents an advance in the treatment of urticaria. "
03/01/2000 - "Mizolastine is a novel second generation antihistamine with additional anti-inflammatory properties which has been shown to be effective in this condition as well as in allergic rhinitis. "
06/01/2001 - "Mizolastine is a second generation antihistamine agent approved in Europe for the treatment of allergic rhinitis and skin conditions for which Sanofi-Synthélabo is developing a pediatric solution. "
07/01/2000 - "Mizolastine is a new non-sedative antihistamine and antiallergic drug proven to be effective and safe in the treatment of allergic rhinitis and urticaria. "
01/01/2001 - "Mizolastine 10 mg/day is effective in allergic rhinitis and chronic idiopathic urticaria. "
05/01/1999 - "Mizolastine is a potent, selective, nonsedating peripherally acting H1-receptor antagonist which is registered for rhinitis and urticaria at a recommended dose of 10 mg once daily. "
|3.||Seasonal Allergic Rhinitis (Hay Fever)
12/01/1998 - "Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis."
01/01/2000 - "In the treatment of seasonal allergic rhinitis, mizolastine 10 mg/day has been shown to be effective in reducing nasal and ocular symptoms. "
04/01/1997 - "The purpose of this study was to determine whether the onset of hay fever symptoms could be delayed in patients known to suffer seasonal allergic rhinoconjunctivitis symptoms if mizolastine was given before the pollen season. "
12/01/1996 - "In 1989, in a double-blind, placebo-controlled trial, we could show that the vigilance of patients suffering from seasonal allergic rhinitis increased significantly more under treatment with an antihistamine (mizolastine) than under placebo. "
02/01/1996 - "This study conforms mizolastine is an effective and well tolerated antihistamine in the treatment of seasonal allergic rhinitis; 10 mg is the optimal dose."
03/01/2000 - "Clinical assessment also indicated that itch intensity and angioedema were improved by mizolastine, and the improvement was sustained throughout the trial. "
04/01/2000 - "In addition mizolastine demonstrated a superiority in prick tests, beneficial effects on angioedema and seemed to provide a faster onset of action."
01/01/1999 - "Angioedema was improved to a clinically significant extent with mizolastine, and loratadine compared with placebo in those patients who had this symptom before treatment. "
04/01/2000 - "Mizolastine had a positive effect on angioedema (85% CI 95% [0.69-1.00]) of patients improved compared with 75% (CI 95% [0.59-0.91]) of the loratadine group and the differential reduction of the mean total duration of episodes in the mizolastine group was higher when compared with the loratadine group (from 13.7 +/- 33.5 hours on day 0 to 5.1 +/- 9.0 hours over the treatment period and from 8.2 +/- 8.8 hours on day 0 to 5.1 +/- 7.8 hours over the treatment period for mizolastine and loratadine, respectively). "
|5.||Perennial Allergic Rhinitis
07/01/2006 - "A randomized, double-blind, placebo-controlled study was carried out with Mizolastine in sixty patients with perennial allergic rhinitis. "
07/01/2006 - "[Mizolastine improves the quality of life in patients with perennial allergic rhinitis: a randomized, double blind, controlled study]."
06/01/2007 - "To investigate the efficacy and safety of Mizolastine in the treatment of perennial allergic rhinitis. "
06/01/2007 - "[Efficacy and safety of Mizolastine in the treatment of perennial allergic rhinitis]."
07/01/2006 - "Mizolastine can not only decrease symptoms scores but also improve the QOL in patients with perennial allergic rhinitis. "
|6.||Histamine (Histamine Dihydrochloride)
|10.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)